DelveInsight’s, “Influenza Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
Key Takeaways from the Influenza Pipeline Report
Request a sample and discover the recent advances in Influenza @ Influenza Pipeline Outlook
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality. The CDC documented that seasonal influenza was responsible for 24,000 to 62,000 deaths during the 2019-2020 season. Information used to generate influenza in-season burden estimates were too low during the 2020-2021 season to provide an estimate. Mortality was highest in infants and elderly persons. Influenza traditionally has been diagnosed on the basis of clinical criteria, but rapid diagnostic tests, which have a high degree of specificity but only moderate sensitivity, are becoming more widely used. The gold standard for diagnosing influenza A and B is a viral culture of nasopharyngeal samples or throat samples.
In elderly or high-risk patients with pulmonary symptoms, perform chest radiography to exclude pneumonia. Prevention of influenza is the most effective management strategy. Influenza A and B vaccine is administered each year before flu season. The CDC analyzes the vaccine subtypes each year and makes any necessary changes for the coming season on the basis of worldwide trends. Traditionally, the vaccine was trivalent (ie, designed to provide protection against three viral subtypes, generally an A-H1, an A-H3, and a B). The first quadrivalent vaccines, which provide coverage against an additional influenza B subtype, were approved in 2012 and were made available for the 2013-2014 flu season. For the 2021-2022 influenza season, all flu vaccines are expected to be quadrivalent.
Latest Breakthroughs and Developments in the Influenza Treatment Landscape
Influenza Pipeline Insight Report
The Influenza Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Influenza, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Influenza Pipeline Landscape.
Influenza Emerging Drugs
Influenza Pipeline Therapeutics Analysis
There are approx. 120+ key companies which are developing therapies for Influenza. The companies which have their Influenza drug candidates in the most advanced stage, i.e. phase III include, Moderna.
Learn more about the novel and emerging influenza pipeline therapies @ Influenza Clinical Trials
Influenza Pipeline Analysis Report
The Influenza Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third party sources etc.
Scope of the Influenza Pipeline Report
Dive deep into rich insights for Influenza Pipeline Assessment, Visit @ Influenza Treatment
Table of content
For further information on the Influenza Pipeline therapeutics, reach out @ Influenza Drugs
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/